Bausch + Lomb 10-Q: Q3 Net Income $32M, Nine-Month Operating Income Jumps to $271M
BLCO sits 39% above its 52-week low of $14.44 on elevated volume (8.3× avg).
Summary
Bausch + Lomb's Q3 10-Q shows $1.375B revenue (+7%), $32M net income and nine-month operating income of $271M versus $1M last year, with operating cash flow of $418M. It also discloses a September FDA warning letter on the Tampa facility and an ~$85M surgical manufacturing acquisition signed October 8.
Key Events · Earnings and Guidance · BLCO
-
Q3 Revenue Up 7% to $1.375B
Product sales of $1.371B drove the quarter; Vision Care rose 5% to $774M, Pharmaceuticals 11% to $367M and Surgical 9% to $234M.
-
Profitability Swing From a Year Ago
Q3 operating income was $155M vs $95M and net income attributable to Bausch + Lomb was $32M ($0.09 per diluted share) vs a $28M loss. Nine-month operating income reached $271M against $1M in 2025.
-
Cash Flow and Balance Sheet Strengthen
Nine-month operating cash flow was $418M vs $147M, and cash and equivalents rose to $513M from $383M at December 31, 2025; total debt principal was $5.065B.
-
FDA Warning Letter on Tampa Facility
A September 2026 warning letter followed a June 2026 Official Action Indicated inspection; the company says it does not require ceasing manufacturing or a product recall and has responded.
Analysis · BLCO · Industrial Applications And Services
The 8-K this morning gave the headline; the 10-Q fills in the quality of the quarter. Revenue of $1.375B (+7%) converted into $155M of operating income versus $95M a year ago, and the nine-month figure went from $1M to $271M — the Pharmaceuticals segment did most of the work, with segment profit up $165M to $289M as XIIDRA and MIEBO moved past their launch spending. Cash generation is the other change: $418M from operations in nine months against $147M, lifting cash to $513M. Two items carry risk. The company received an FDA warning letter in September tied to the Tampa facility, though it says no manufacturing halt or recall is required. And it agreed on October 8 to buy ophthalmic surgical manufacturing businesses for about $85M cash, closing in Q4 — a modest bolt-on that adds to the $75M CEO severance payable after quarter-end.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 31.1% of the 1661 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLCO was trading at $20.08 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $7.3B. The 52-week trading range was $14.44 to $20.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.